Hemogenyx Pharmaceuticals (LON:HEMO) Shares Up 3.3% – Still a Buy?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares shot up 3.3% on Thursday . The company traded as high as GBX 790.45 and last traded at GBX 790. 19,094 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 28,465 shares. The stock had previously closed at GBX 764.50.

Hemogenyx Pharmaceuticals Trading Up 6.9%

The stock has a market capitalization of £56.03 million, a PE ratio of -4.83 and a beta of 1.50. The company has a quick ratio of 6.72, a current ratio of 1.38 and a debt-to-equity ratio of 167.66. The business’s 50-day moving average is GBX 773.68 and its two-hundred day moving average is GBX 789.20.

Hemogenyx Pharmaceuticals (LON:HEMO) last announced its earnings results on Thursday, April 30th. The company reported GBX (170.60) EPS for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.